Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO

doi:10.19401/j.cnki.1007-3639.2023.11.003

China Oncology ›› 2023, Vol. 33 ›› Issue (11): 989-992.doi: 10.19401/j.cnki.1007-3639.2023.11.003

• Specialist' Commentary • Previous Articles Next Articles

Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO

ZHANG Xiaowei(), LIU Xin, LUO Zhiguo()

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2023-11-15 Revised:2023-11-18 Online:2023-11-30 Published:2023-12-14

Abstract

Abstract:

Cancer of unknown primary (CUP) is a metastatic syndrome with an unidentifiable primary tumor even after comprehensive clinical and pathological investigations, accounting for approximately 2%-5% of all newly diagnosed cancers. CUP has some common features including aggressiveness, early dissemination and poor prognosis. With the application of novel molecular tests and drugs, the diagnostic value of gene expression assay and genomic tests in characterizing the molecular features has become increasingly prominent, and new treatment options such as molecular-guided targeted therapy and immunotherapy have become available. This article reviewed the clinical trials of CUP reported at 2023 European Society for Medical Oncology (ESMO) Congress.

Key words: Cancer of unknown primary, 90-gene expression assay, Tissue of origin, Site-specific therapy, Precision medicine

CLC Number:

R730.5

ZHANG Xiaowei, LIU Xin, LUO Zhiguo. Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO[J]. China Oncology, 2023, 33(11): 989-992.

References 10

[1]	KRÄMER A, BOCHTLER T, PAULI C, et al. Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(3): 228-246. doi: 10.1016/j.annonc.2022.11.013
[2]	RASSY E, PAVLIDIS N. The currently declining incidence of cancer of unknown primary[J]. Cancer Epidemiol, 2019, 61: 139-141. doi: S1877-7821(19)30056-6 pmid: 31254795
[3]	SUN W, WU W, WANG Q F, et al. Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients[J]. J Transl Med, 2022, 20(1): 114. doi: 10.1186/s12967-022-03318-6 pmid: 35255924
[4]	LUO Z, LIU X, ZHANG X, et al. A randomized phase Ⅲ trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary[J]. Ann Oncol, 2023, 34: S712.
[5]	HAINSWORTH J D, RUBIN M S, SPIGEL D R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute[J]. J Clin Oncol, 2013, 31(2): 217-223. doi: 10.1200/JCO.2012.43.3755 pmid: 23032625
[6]	MORAN S, MARTÍNEZ-CARDÚS A, SAYOLS S, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis[J]. Lancet Oncol, 2016, 17(10): 1386-1395. doi: S1470-2045(16)30297-2 pmid: 27575023
[7]	HAYASHI H, TAKIGUCHI Y, MINAMI H, et al. Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial[J]. JAMA Oncol, 2020, 6(12): 1931-1938. doi: 10.1001/jamaoncol.2020.4643 pmid: 33057591
[8]	HAYASHI H, KURATA T, TAKIGUCHI Y, et al. Randomized phase Ⅱ trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site[J]. J Clin Oncol, 2019, 37(7): 570-579.
[9]	FIZAZI K, MAILLARD A, PENEL N, et al. A phase Ⅲ trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)[J]. Ann Oncol, 2019, 30: v851.
[10]	MILESHKIN L. Primary analysis of efficacy and safety in the CUPISCO trial: a randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)[J]. Ann Oncol, 2023, 34: S1254-S1255. doi: 10.1016/j.annonc.2023.10.006

Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 10

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	Society of Cancer of Multiple and Unknown Primary of China Anti-Cancer Association Yuguang . China Anti-Cancer Association guideline for diagnosis and treatment of cancer of multiple and unknown primaries (2023 edition) [J]. China Oncology, 2023, 33(4): 403-422.
[2]	GAO Heli, XU Jin, CHEN Jie, YU Xianjun. Updates on precision medicine of pancreatic neuroendocrine tumor [J]. China Oncology, 2023, 33(11): 993-1001.
[3]	CAO Xiaoshan, CONG Binbin. The progress of treatment for triple-negative breast cancer in the era of precision medicine [J]. China Oncology, 2019, 29(12): 971-976.
[4]	WANG Qifeng, XU Qinghua, CHEN Jinying, et al. Identification and validation of a novel gene expression signature for diagnosing tumor tissue origin [J]. China Oncology, 2016, 26(10): 801-812.